Certification expands Viralgen’s capacity threefold and positions the company as a worldleading
CDMO.
New facility operates single-use bioreactors from 50 to 2,000 liters and manufactures
research, clinical and commercial grade rAAV vectors using Pro10™, the leading cell line on the
market.
Viralgen Vector Core (Viralgen), an independently operated subsidiary of
Asklepios BioPharmaceutical, Inc. (AskBio), and a member of the Bayer worldwide group of companies,
has received Certified Good Manufacturing Practices (cGMP) certification for the manufacture of human
medicinal products, investigational medicinal products and sterile or biological active substances. This
certification was granted following a successful inspection by the Spanish Agency for Medicines and
Medical Devices (AEMPS), a part of the European Medicines Agency (EMA) network. The company now
operates two facilities in San Sebastian, Spain, with seven state-of-the-art single-use suites that have up
to 2,000 liters of manufacturing capacity, making it a world-leading contract development and
manufacturing organization (CDMO).
Viralgen is now licensed for the commercial manufacturing of recombinant adeno-associated virus
(rAAV) gene therapies up to 2,000 liters and has completed seven successful runs at this maximum scale.
This first phase of the expansion of the new facility, which has added 300,000 square feet of clinical and
commercial rAAV manufacturing, is now complete. The new facility currently has three independent
state-of-the-art quality control labs and commercial manufacturing suites with 500- and 2,000-liter
single-use bioreactors. Viralgen anticipates opening additional manufacturing, science and technology
(MSAT) and analytical development space at the same facility at the end of Q1 2023.
“Being a fully integrated CDMO, we offer a continuum of products and services, including process,
analytical development, stability studies and fill and finish for all types of rAAV serotypes,” said Jimmy
Vanhove, CEO of Viralgen. “This can significantly shorten the time to market, help with predictable cost
of goods and reduce the waiting time experienced by patients who have run out of options and hope for
breakthrough treatments.”
With this approval, Viralgen expands its ability to partner with customers in the rAAV space that are
initiating Phase III studies and seeking approvals to commercialize their products. This builds on the
company’s achievement of its 2022 pivotal milestone, which was the manufacturing over 135 batches of
clinical and preclinical material, and its enabling more than 24 INDs since its inception in 2019.
“With this certification, we have three times the rAAV production capacity we had previously. This
solidifies our position as a global leader in the CDMO rAAV field”, said Javier García, co-founder and
Chairman of the Board of Viralgen. “We are now able to manufacture at the industry’s largest scale and
supply Phase III and commercial products for our global customers.”
Viralgen was created in 2017 to respond to the unmet need for the manufacturing of gene therapies,
with the goal of helping broaden access to these life-saving therapeutics around the world. Viralgen
specializes in the production of rAAV vectors and has built an optimized facility that maximizes the
throughput and efficiency of the proprietary Pro10™ based suspension manufacturing platform,
enabling industry-leading yields, scalability and speed to market. Viralgen is a fully integrated company,
which supplies research, cGMP and commercial grade material from 250 to 2,000 liters in scale,
including process development, formulation and filling.
